V. Amber

发表

Observational study of ezetimibe discontinuation in primary care practices in the UK

G. Hall, C. O'regan, V. Amber, 2013, Current medical research and opinion.

Usage of troponin in the real world: a lesson for the introduction of biochemical assays.

K. Rajappan, K. Fox, E. Murphy, 2005, QJM : monthly journal of the Association of Physicians.

Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.

S. Bloom, M. Ghatei, K. Murphy, 2005, The Journal of clinical endocrinology and metabolism.

neonatal and juvenile IUGR rats determinants of chromatin structure in brains of Uteroplacental insufficiency affects epigenetic

C. Callaway, S. J. James, Xing Yu, 2015 .

PYY3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans

K. Wynne, N. Martin, S. Bloom, 2010, Diabetes.

Kisspeptin‐54 at high doses acutely induces testicular degeneration in adult male rats via central mechanisms

M. Patterson, M. Ghatei, G. Stamp, 2009, British journal of pharmacology.

Serum molecular signatures of weight change during early breast cancer chemotherapy.

H. Keun, J. Stebbing, S. Bloom, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.

S. Bloom, M. Ghatei, K. Murphy, 2007, The Journal of clinical endocrinology and metabolism.

A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study

M. Labopin, D. Blaise, M. Mohty, 2021, Bone Marrow Transplantation.

liver IUGR rat day 0 affects DNA-histone H3 positioning in changes in histone H3 covalent modifications and Uteroplacental insufficiency induces site-specific

C. Callaway, Xing Yu, R. McKnight, 2015 .

New biomarkers in breast cancer: microRNAs and leptins--where are we now?

J. Stebbing, V. Amber, T. Keith, 2007, Biomarkers in medicine.

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol

F. Locatelli, F. Ciceri, F. Fagioli, 2015 .

Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy

H. Keun, J. Stebbing, S. Bloom, 2009, Clinical Cancer Research.

A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results

P. Richardson, S. Grupp, A. Pagliuca, 2021, Blood.

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care – a retrospective database study

K. D’Oca, B. Ambegaonkar, D. Mills, 2013, International journal of clinical practice.

Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content.

Jimmy D Bell, J. Fitzpatrick, Elizabeth Louise Thomas, 2007, Atherosclerosis.

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.

P. Richardson, S. Grupp, M. Mohty, 2023, The Lancet. Haematology.

Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

D. Wood, J. Ferrières, C. Jünger, 2013, Cardiology.